ECHOCARDIOGRAPHIC DETERMINANTS OF CLINICAL OUTCOME IN SUBJECTS WITH CORONARY-ARTERY DISEASE (THE FRAMINGHAM HEART-STUDY)

Echocardiographic predictors of clinical outcome were examined in subjects from the Framingham Heart Study with overt coronary artery disease. The study population consisted of 185 men and 147 women with coronary artery disease who underwent M-mode echocardiography and were followed for a mean of 3.90 years. At baseline, 37 men (18.4%) and 16 women (10.9%) had reduced fractional shortening, 43 men (23.2%) and 28 women (19%) had left ventricular (LV) dilatation, and 76 men (41%) and 76 women (51.7%) had LV hypertrophy. During the follow-up period new cardiovascular disease events (coronary disease, stroke, transient ischemic attack, claudication, heart failure and deaths from cardiovascular disease) occurred in 60 men (32%) and 58 women (39%). With use of age-adjusted proportional hazards analyses, LV mass/height in men (relative risk [RR] = 1.2S/SO g/m increment, 95% confidence interval [CI] 1.01 to 1.55) and LV end-diastolic diameter in women (RR = 1.36/5 mm increment, 95% CI 1.05 to 1.76) were predictors of new cardiovascular disease events. Cardiovascular risk was also associated with LV end-systolic diameter in both sexes (in men RR = 1.28/1 SD increment, 95% CI 1.02 to 1.63; in women RR 1.40/1 standard deviation increment, 95% CI 1.09 to 1.82). Reduced fractional shortening alone (RR = 1.91, 95% CI 1.11 to 3.3 1) and in combination with LV dilatation (RR = 2.13, 95% CI 1.13 to 4.02) was associated with the incidence of new cardiovascular disease outcomes in men. In women, cardiovascular risk was increased with LV hypertrophy (RR = 2.30, 95% CI 1.29 to 4.12), high LV wall thickness (RR 3.36 95% CI = 1.18 to 9.55), high LV end-systolic diameter (RR = 2.59, 95% CI 1.45 to 4.62) and a combination of low fractional shortening and LV dilatation (RR = 3.25, 95% CI 1.28 to 8.25). Thus, M-mode echocardiography has prognostic value in identifying subjects with coronary artery disease who are at increased risk for new morbid or fatal events.